{"entity":{"id":"nature-cancer","kind":"journal","name":"Nature Cancer","aka":["Nat Cancer","src-nature-cancer"],"tldr":"Nature Cancer is Nature's cancer-specific research journal, launched in 2020, spanning basic biology to translational and clinical cancer studies.","summary":"Nature Cancer (Nat Cancer) is Nature's cancer-specific research journal, launched in 2020, appearing monthly and published by Springer Nature on a hybrid access model. It spans basic biology to translational and clinical cancer studies, publishing tumour biology, immuno-oncology, computational and AI methods for cancer, and early-phase trial correlative science, with a deliberate remit to cover health-policy and access issues as well. Its readers are cancer researchers across the basic-to-clinical spectrum. Within OnCo it has its own Nature Cancer source feed and is linked from the biographies of Todd Golub and Jakob Nikolas Kather, and it is where a reader would look for computational and AI cancer methods and correlative trial science.","asOf":"2026-09-09","links":[{"label":"Nature Portfolio","url":"https://www.nature.com"}],"tags":[],"related":["src-npj-precision-oncology"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Holds: Cancer biology and translational studies across the spectrum. Access: Paywalled."],"publisher":"Springer Nature","url":"https://www.nature.com/natcancer/","issn":"2662-1347","scope":"basic cancer biology","access":"hybrid","founded":2020,"impactFactor":{"value":23.5,"year":2023,"source":"Clarivate Journal Citation Reports 2024 (2023 JIF)"},"matchNames":["Nature Cancer","Nat Cancer"]},"route":"/journals/nature-cancer/","neighbours":{"collection":[{"id":"src-npj-precision-oncology","kind":"collection","name":"npj Precision Oncology","route":"/collections/src-npj-precision-oncology/"}],"paper":[{"id":"paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020","kind":"paper","name":"A unifying paradigm for transcriptional heterogeneity and squamous features in pancreatic ductal adenocarcinoma","route":"/key-papers/paper-hayashi-squamous-basal-like-pancreatic-nat-cancer-2020/"},{"id":"paper-ackerman-nat-cancer","kind":"paper","name":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","route":"/key-papers/paper-ackerman-nat-cancer/"},{"id":"paper-gemstone-302-nat-cancer-2023-update","kind":"paper","name":"Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC","route":"/key-papers/paper-gemstone-302-nat-cancer-2023-update/"},{"id":"paper-antoine-italiano-nat-cancer-2021","kind":"paper","name":"Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression","route":"/key-papers/paper-antoine-italiano-nat-cancer-2021/"}],"person":[{"id":"jakob-nikolas-kather","kind":"person","name":"Jakob Nikolas Kather","route":"/people/jakob-nikolas-kather/"},{"id":"todd-golub","kind":"person","name":"Todd R. Golub","route":"/people/todd-golub/"}]}}